Innovent Biologics (1801) Stock Statistics & Valuation Metrics

Innovent Biologics has a market cap or net worth of HK$84.13B. The enterprise value is HK$75.19B.

Innovent Biologics has 1,649,528,700 shares outstanding. The number of shares has decreased by -2.65% in one year.

Innovent Biologics’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is -5.16%.

The current PE Ratio of Innovent Biologics is -591.18. Innovent Biologics’s PEG ratio is -9.28.

In the last 12 months, Innovent Biologics had revenue of 9.42B and earned -94.63M in profits. Earnings per share was -0.06.

In the last 12 months, operating cash flow was -215.63M and capital expenditures -699.51M, giving a free cash flow of -915.15M billion.

Innovent Biologics pays an annual dividend of ―, resulting in a dividend yield of ―

Innovent Biologics upcoming earnings date is Aug 27, 2025, TBA Not Confirmed.

Innovent Biologics as a current ratio of 2.35, with Debt / Equity ratio of 21.58%

In the past 12 months, Innovent Biologics has paid 16.01M in taxes.

Innovent Biologics EV to EBITDA ratio is -106.74, with an EV/FCF ratio of 0.00.

Innovent Biologics has HK$7.88B in cash and marketable securities with ¥2.83B in debt, giving a net cash position of -HK$5.05B billion.

Gross margin is 74.40%, with operating margin of -8.02%, and net profit margin of -1.00%.

The average price target for Innovent Biologics is HK$52.04, which is 11.43% higher than the current price. The consensus rating is Moderate Buy